SyncThink

SyncThink

Pioneering neuro-technology with advanced eye-tracking for reliable concussion diagnostics.

Founded 2009 11-50 employees Seed Total: $3.60M Biotechnology, Health Care +3

SyncThink is a pioneering neuro-technology startup with a focus on advanced eye-tracking for reliable concussion diagnostics. Established in 2009 by Dr. Jamshid Ghajar, the company is headquartered in Palo Alto, CA, with an affiliate office in New York City. SyncThink has forged top-tier alliances with esteemed research institutions such as the Brain Trauma Foundation, Stanford University, Mass General Hospital, and the Pac-12. Notably, the company has secured over $36 million in R&D funding through contracts from the US Department of Defense since 2008. The company's flagship product, the EYE-SYNC device, is an all-in-one, head-mounted eye-tracking system designed for rapid and reliable attention focus screening. It boasts multiple FDA-approved applications, with potential uses in neuro-diagnostics in military and sports, children's attention development, brain performance enhancement, fatigue evaluation, and pharmaceuticals. The proprietary technology behind EYE-SYNC comprises eleven issued patents and six pending, covering various aspects of their hardware, analytics, and scientific platform. Notably, the last investment, a Seed Round investment at 11 March 2019, was made by StartUp Health. The EYE-SYNC device has received FDA approval and offers benefits such as quick results (under 60 seconds), accuracy, portability, and established metrics. Overall, SyncThink's innovative approach and strategic collaborations position it as a key player in the biotechnology, healthcare, and pharmaceutical industries, with potential for substantial impact in neuro-technology and concussion diagnostics.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	Undisclosed	1	StartUp Health	11 Mar 2019
Seed Round	$3.50M	3	Quadrant Management, Raul Fernandez +1	10 Jan 2018
Grant	$100.00K	1	MassChallenge	13 Jun 2017
Seed Round	Undisclosed	2	Quadrant Management, Alan Quasha	01 Jan 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

Undisclosed

StartUp Health

11 Mar 2019

Seed Round

$3.50M

Quadrant Management, Raul Fernandez +1

10 Jan 2018

Grant

$100.00K

MassChallenge

13 Jun 2017

Seed Round

Undisclosed

Quadrant Management, Alan Quasha

01 Jan 2011

FAQ About SyncThink

Pioneering neuro-technology with advanced eye-tracking for reliable concussion diagnostics.

SyncThink was founded in 2009.

SyncThink operates in Biotechnology, Health Care, Medical Devices, Pharmaceutical and VR/AR. Its work centres on Neuro-technology, Eye-tracking, Concussion diagnostics and Medical devices.

SyncThink has approximately 11-50 employees.

SyncThink has completed 4 funding rounds, raising a total of $3.60M. The latest funding stage is Seed.

Top alternatives and competitors to SyncThink include NeuroCatch®, NeuroScouting, Vytal, RH Nanopharmaceuticals , BrainMaster Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

SyncThink and NeuroCatch® are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About SyncThink

Funding Rounds & Investors (4)

SyncThink Alternatives & Competitors

FAQ About SyncThink